Everolimus-Eluting Second-Generation Stents for Treatment of De Novo Lesions in Patients with Cardiac Allograft Vasculopathy.

Content Provider	Europe PMC
Author	Pyka, Łukasz Hawranek, Michał Szyguła-Jurkiewicz, Bożena Desperak, Piotr Szczurek, Wioletta Lekston, Andrzej Gąsior, Mariusz Zembala, Michał O. Pawlak, Szymon Zembala, Marian Przybyłowski, Piotr
Copyright Year	2020
Abstract	BackgroundCardiac allograft vasculopathy is a major cause of cardiac allograft rejection. Percutaneous coronary intervention has become the main form of treatment of significant focal lesions. Despite the significance of the problem, data remain scarce. With a large population of transplant recipients undergoing coronary angiography at our center, we decided to analyze the implications of the use of everolimus-eluting second-generation stents by performing 6-month clinical and angiographic follow-up.Material/MethodsFrom December 2012 and August 2019, 319 patients after heart transplantation undergoing coronary angiography at our institution were analyzed. Subsequently, 22 patients underwent de novo angioplasty with second-generation everolimus-eluting stents. The primary study endpoint was angiographic restenosis as evaluated by quantitative coronary angiography. Secondary outcomes included binary restenosis, target lesion revascularization, and cardiac death during the follow-up period (6 months).ResultsPatient comorbidities included hypertension (77.3%), type 2 diabetes mellitus (68.2%), dyslipidemia (68.2%), and obesity (31.8%). Primary success was obtained in all of the treated lesions. The analysis of quantitative coronary angiography after 6-month follow-up revealed low late lumen loss (0.22±0.40). Significant restenosis was observed in 1 of the cases. There were no deaths in the 6-month observation period.ConclusionsIn the analyzed population, invasive strategy with second-generation everolimus-eluting stents for de novo lesions in cardiac allograft vasculopathy resulted in a low rate of binary restenosis, low late lumen loss, and no deaths during the 6-month follow-up.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC7163333&blobtype=pdf
ISSN	14259524
Journal	Annals of Transplantation [Ann Transplant]
Volume Number	25
PubMed Central reference number	PMC7163333
PubMed reference number	32253369
e-ISSN	23290358
DOI	10.12659/aot.921266
Language	English
Publisher	International Scientific Literature, Inc.
Publisher Date	2020-04-07
Access Restriction	Open
Rights License	This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) © Ann Transplant, 2020
Subject Keyword	Coronary Artery Disease Drug-Eluting Stents Transplantation Tolerance
Content Type	Text
Resource Type	Article
Subject	Transplantation